Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 2035-2040

  Gross, Coleman ^a   Stamey, Thomas ^a   Hancock, Steven ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

24, 25 dihydroxyvitamin D3; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

CALCITRIOL; CALCIUM;

ADULT; AGED; ARTICLE; CALCIUM URINE LEVEL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENT CANCER;

EID: 0032439651     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63236-1     Document Type: Article

References (32)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1996. CA, 46: 5, 1996.
2. Santen, R. J.: Clinical Review 37: Endocrine treatment of prostate cancer. J. Clin. Endocr. Metab., 75: 685, 1992.
3. Crawford, E. D., DeAntonio, E. P., Labrie, F., Schroder, F. H. and Geller, J.: Endocrine therapy of prostate cancer: optimal form and appropriate timing. J. Clin. Endocr. Metab., 80: 1062, 1995.
4. Schwartz, G. G. and Hulka, B. S.: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis.) Anticancer Res., 10: 1307, 1990.
5. Hanchette, C. L. and Schwartz, G. G.: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer, 70: 2861, 1992.
6. Corder, E. H., Guess, H. A., Hulka, B. S., Friedman, G. D., Sadler, M., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogelman, J. H. and Orentreich, N.: Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev., 2: 467, 1993.
7. Manglesdorf, D. J. and Evans, R. M.: The RXR heterodimers and orphan receptors. Cell, 83: 841, 1995.
8. Feldman, D., Malloy, P. J. and Gross, C.: Vitamin D: metabolism and action. In: Osteoporosis. Edited by R. Marcus, D. Feldman and J. Kelsey. New York: Academic Press, chapt. 6, pp. 205-235, 1996.
9. Bikle, D. D.: Clinical counterpoint. Vitamin D: new actions, new analogs, new therapeutic potential. Endocr. Rev., 13: 765, 1992.
10. Gross, C., Peehl, D. and Feldman, D.: Vitamin D and prostate cancer. In: Vitamin D. Edited by D. Feldman, J. W. Pike and F. H. Glorieux. San Diego: Academic Press, chapt. 66, pp. 1125-1139, 1997.
11. Miller, G. J., Stapleton, G. E., Ferrara, J. A., Lucia, M. S., Pfister, S., Hedlund, T. E. and Upadhya, P.: The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D3. Cancer Res., 52: 515, 1992.
12. Skowronski, R. J., Peehl, D. M. and Feldman, D.: Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132: 1952, 1993.
13. Peehl, D. M., Skowronski, R. J., Leung, G. K., Wong, S. T., Stamey, T. A. and Feldman, D.: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res, 54: 805, 1994.
14. Skowronski, R. J., Peehl, D. M. and Feldman, D.: Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology, 136: 20, 1995.
15. Miller, G. J., Stapelton, G. E., Hedlund, T. E. and Moffatt, K. A.: Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1: 997, 1995.
16. Taylor, J. A., Hirvonen, A., Watson, M., Pittman, G., Mohler, J. L. and Bell, D. A.: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 56: 4108, 1996.
17. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W. and Coetzee, G. A.: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166, 1997.
18. Feldman, D.: Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J. Natl. Cancer Inst., 89: 109, 1997.
19. Osborn, J. L., Schwartz, G. G., Smith, D. C., Bahnson, R., Day, R. and Trump, D. L.: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol. Oncol., 1: 195, 1995.
20. Schmid, H.-P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993.
21. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
22. Stamey, T. A. and Kabalin, J. N.: Prostate specific antigen in the diagnosis and teratment of adenocarcinoma of the prostate. I. Untreated patients. J. Urol., 141: 1070, 1989.
23. Schaefer, K., Umlauf, E. and von Herrath, D.: Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night. Amer. J. Kidney Dis., 19: 460, 1992.
24. Villa, M. L., Marcus, R., Ramirez Delay, R. and, Kelsey, J. L.: Factors contributing to skeletal health of postmenopausal Mexican-American women. J. Bone Miner. Res., 10: 1233, 1995.
25. Holloway, L., Kohlmeier, L., Kent, K. and Marcus, R.: Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J. Clin. Endocr. Metab., 82: 1111, 1997.
26. Kasiske, B. L. and Keane, W. F.: Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: The Kidney. Edited by B. M. Brenner. Philadelphia: W. B. Saunders, vol. 2, chapt. 26, pp. 1137-1174, 1996.
27. Bertoli, M., Luisetto, C., Ruffatti, A., Urso, M. and Romagnoli, G.: Renal function during calcitriol therapy in chronic renal failure. Clin. Nephrol., 33: 98, 1990.
28. 3) for the treatment of psoriasis. Brit. J. Dermatol., 134: 1070, 1996.
29. Lemann, J., Jr.: Pathogenesis of idiopathic hypercalciuria and nephrolithiasis. In: Disorders of Bone and Mineral Metabolism. Edited by F. L. Coe and M. J. Favus. New York: Raven Press, chapt. 32, pp. 685-706, 1992.
30. Coe, F. L. and Parks, J. H.: New insights into the pathophysiology and treatment of nephrolithiasis: new research venues. J. Bone Miner. Res., 12: 522, 1997.
31. Raisz, L. G., Trummel, C. L., Holick, M. F. and DeLuca, H. F.: 1,25-Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science, 175: 768, 1972.
32. Maierhofer, W. J., Gray, R. W., Cheung, H. S. and Lemann, J.: Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int., 24: 555, 1983.